Stoke Therapeutics (STOK) Competitors

Stoke Therapeutics logo
$26.63 -0.05 (-0.19%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$26.63 0.00 (0.00%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

STOK vs. ORKA, IONS, GRAL, MIRM, and LGND

Should you buy Stoke Therapeutics stock or one of its competitors? Stoke Therapeutics's main competitors and comparable companies include Oruka Therapeutics (ORKA), Ionis Pharmaceuticals (IONS), GRAIL (GRAL), Mirum Pharmaceuticals (MIRM), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Stoke Therapeutics compare to Oruka Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Stoke Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$184.42M9.45-$6.89M-$3.77N/A
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A

In the previous week, Oruka Therapeutics had 24 more articles in the media than Stoke Therapeutics. MarketBeat recorded 28 mentions for Oruka Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Oruka Therapeutics' score of -0.01 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
6 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Stoke Therapeutics currently has a consensus price target of $44.17, suggesting a potential upside of 65.85%. Oruka Therapeutics has a consensus price target of $141.80, suggesting a potential upside of 42.89%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Stoke Therapeutics is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Oruka Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -862.07%. Oruka Therapeutics' return on equity of -19.34% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics-862.07% -67.30% -58.52%
Oruka Therapeutics N/A -19.34%-18.74%

Stoke Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Stoke Therapeutics and Oruka Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Stoke Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ionis Pharmaceuticals has a net margin of -56.98% compared to Stoke Therapeutics' net margin of -862.07%. Stoke Therapeutics' return on equity of -67.30% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-56.98% -120.62% -16.99%
Stoke Therapeutics -862.07%-67.30%-58.52%

Stoke Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$944M4.94-$381.39M-$3.32N/A
Stoke Therapeutics$184.42M9.45-$6.89M-$3.77N/A

Ionis Pharmaceuticals presently has a consensus target price of $75.71, suggesting a potential upside of 170.31%. Stoke Therapeutics has a consensus target price of $44.17, suggesting a potential upside of 65.85%. Given Ionis Pharmaceuticals' higher possible upside, equities research analysts plainly believe Ionis Pharmaceuticals is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Ionis Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

In the previous week, Ionis Pharmaceuticals had 35 more articles in the media than Stoke Therapeutics. MarketBeat recorded 39 mentions for Ionis Pharmaceuticals and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Ionis Pharmaceuticals' score of 0.11 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
6 Very Positive mention(s)
5 Positive mention(s)
14 Neutral mention(s)
7 Negative mention(s)
0 Very Negative mention(s)
Neutral
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Ionis Pharmaceuticals beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

GRAIL currently has a consensus price target of $128.80, indicating a potential upside of 21.97%. Stoke Therapeutics has a consensus price target of $44.17, indicating a potential upside of 65.85%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

GRAIL has a net margin of -243.80% compared to Stoke Therapeutics' net margin of -862.07%. GRAIL's return on equity of -16.13% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-243.80% -16.13% -14.38%
Stoke Therapeutics -862.07%-67.30%-58.52%

Stoke Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$147.17M32.26-$408.35M-$9.50N/A
Stoke Therapeutics$184.42M9.45-$6.89M-$3.77N/A

GRAIL has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, GRAIL had 4 more articles in the media than Stoke Therapeutics. MarketBeat recorded 8 mentions for GRAIL and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat GRAIL's score of 0.60 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Stoke Therapeutics beats GRAIL on 7 of the 13 factors compared between the two stocks.

How does Stoke Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Mirum Pharmaceuticals had 13 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Mirum Pharmaceuticals and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Mirum Pharmaceuticals' score of 0.74 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mirum Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Stoke Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum Pharmaceuticals$521.31M11.47-$23.36M-$15.47N/A
Stoke Therapeutics$184.42M9.45-$6.89M-$3.77N/A

Mirum Pharmaceuticals has a net margin of -134.75% compared to Stoke Therapeutics' net margin of -862.07%. Stoke Therapeutics' return on equity of -67.30% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals-134.75% -97.25% -12.59%
Stoke Therapeutics -862.07%-67.30%-58.52%

Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus target price of $155.56, suggesting a potential upside of 69.87%. Stoke Therapeutics has a consensus target price of $44.17, suggesting a potential upside of 65.85%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Mirum Pharmaceuticals beats Stoke Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Stoke Therapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Ligand Pharmaceuticals has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$268.09M22.51$124.45M$2.24134.69
Stoke Therapeutics$184.42M9.45-$6.89M-$3.77N/A

Ligand Pharmaceuticals has a net margin of 20.27% compared to Stoke Therapeutics' net margin of -862.07%. Ligand Pharmaceuticals' return on equity of 5.22% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals20.27% 5.22% 2.74%
Stoke Therapeutics -862.07%-67.30%-58.52%

Ligand Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ligand Pharmaceuticals currently has a consensus price target of $355.38, suggesting a potential upside of 17.79%. Stoke Therapeutics has a consensus price target of $44.17, suggesting a potential upside of 65.85%. Given Stoke Therapeutics' higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

In the previous week, Ligand Pharmaceuticals had 11 more articles in the media than Stoke Therapeutics. MarketBeat recorded 15 mentions for Ligand Pharmaceuticals and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Ligand Pharmaceuticals' score of 0.80 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Ligand Pharmaceuticals beats Stoke Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STOK vs. The Competition

MetricStoke TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.71B$4.15B$7.83B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5633.3627.60
Price / Sales9.4516.048.595.73
Price / CashN/A26.3721.9322.50
Price / Book4.944.074.403.70
Net Income-$6.89M-$22.86M$3.52B$392.17M
7 Day Performance-2.13%-6.15%-4.48%-3.37%
1 Month Performance10.18%-4.92%-3.53%-5.82%
1 Year Performance-1.19%-3.09%0.12%-6.24%

Stoke Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STOK
Stoke Therapeutics
2.1368 of 5 stars
$26.63
-0.2%
$44.17
+65.9%
+0.5%$1.71B$184.42MN/A170
ORKA
Oruka Therapeutics
2.5403 of 5 stars
$104.56
+1.7%
$133.00
+27.2%
+266.5%$6.71BN/AN/A68
IONS
Ionis Pharmaceuticals
3.5749 of 5 stars
$31.00
-21.4%
$85.33
+175.3%
-60.9%$6.67B$944MN/A1,402
GRAL
GRAIL
2.505 of 5 stars
$128.08
+5.5%
$128.80
+0.6%
+32.6%$6.42B$147.17MN/A910
MIRM
Mirum Pharmaceuticals
2.8 of 5 stars
$93.18
-0.6%
$154.94
+66.3%
+28.2%$6.33B$521.31MN/A433

Related Companies and Tools


This page (NASDAQ:STOK) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners